ABSTRACT
Up to the present time, six PSs have received federal approval in the RF for clinical application: PG, Photosens, and Alasens (AS) (FSUE SSC, Niopic, Moscow, RF), Radachlorin (RC, RadaPharma, Moscow, RF), Photodithazin (PD, Veta-Grand, Moscow, RF), and Photolon (PL, RUE Bel medpreparaty, Belarus). Clinical trials for PL were done in Belarus and the approval in the RF was
achieved in 2006 after a positive clinical study in patients with basal cell cancer (BCC).
